Drug Patents owned by Biohaven Ireland

1. Drug name - NURTEC ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8314117 BIOHAVEN IRELAND CGRP receptor antagonists
Feb, 2031

(8 years from now)

US8759372 BIOHAVEN IRELAND N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt
Feb, 2033

(10 years from now)

CN102656159A BIOHAVEN IRELAND Cgrp Receptor Antagonists
Oct, 2030

(8 years from now)

CN102656159B BIOHAVEN IRELAND Cgrp Receptor Antagonists
Oct, 2030

(8 years from now)

CN104136437A BIOHAVEN IRELAND N - (5S, 6S, 9R) -4-(2-Oxo-3, -2 - Dihydro - -1H - Imidazo [4, 5-B-A] Naphthyridine - -1 - Yl) - Piperidine - -1 - Carboxylic Acid 5-Amino - -6-(2, 3 Phenyl) -6, 7, 8, 9-Tetrahydropyranyl -5H - Cyclohepta [B] -9 - Ester Hemisulfate
Feb, 2033

(10 years from now)

CN104136437B BIOHAVEN IRELAND N - (5S, 6S, 9R) -4-(2-Oxo-3, -2 - Dihydro - -1H - Imidazo [4, 5-B-A] Naphthyridine - -1 - Yl) - Piperidine - -1 - Carboxylic Acid 5-Amino - -6-(2, 3 Phenyl) -6, 7, 8, 9-Tetrahydropyranyl -5H - Cyclohepta [B] -9 - Ester Hemisulfate
Feb, 2033

(10 years from now)

IN308116B BIOHAVEN IRELAND Cgrp Receptor Antagonists
Oct, 2030

(8 years from now)

IN201203373P4 BIOHAVEN IRELAND Cgrp Receptor Antagonists
Oct, 2030

(8 years from now)

EP2488512A1 BIOHAVEN IRELAND Cgrp Receptor Antagonists
Oct, 2030

(8 years from now)

EP2488512B1 BIOHAVEN IRELAND Cgrp Receptor Antagonists
Oct, 2030

(8 years from now)

EP2820016A1 BIOHAVEN IRELAND N- (5S, 6S, 9R) - 5 -Amino- 6 - (2, 3 - Difluorophenyl) -6, 7, 8, 9 - Tetrahydro - 5H - Cyclohepta [B]Pyridin-9 -Yl- 4 - (2 - Oxo-2, 3 - Dihydro - 1H- Imidazo [4, 5 -B]Pyridin - 1 - Yl) Piperidine - 1 - Carboxylate, Hemisulfate Salt
Feb, 2033

(10 years from now)

EP3254681A1 BIOHAVEN IRELAND N-(5S,6S,9R)-5-Amino-6-(2,3-Difluorophenyl)-6,7,8,9-Tetrahydro-5H-Cyclohepta[B]Pyridin-9-Yl-4-(2-Oxo-2,3-Dihydro-1H-Imidazo[4,5-B]Pyridin-1-Yl)Piperidine-1-Carboxylate Salt
Feb, 2033

(10 years from now)

EP3254681B1 BIOHAVEN IRELAND N-(5S,6S,9R)-5-Amino-6-(2,3-Difluorophenyl)-6,7,8,9-Tetrahydro-5H-Cyclohepta[B]Pyridin-9-Yl-4-(2-Oxo-2,3-Dihydro-1H-Imidazo[4,5-B]Pyridin-1-Yl)Piperidine-1-Carboxylate Salt
Feb, 2033

(10 years from now)

EP2820016B1 BIOHAVEN IRELAND N- (5S, 6S, 9R) - 5 -Amino- 6 - (2, 3 - Difluorophenyl) -6, 7, 8, 9 - Tetrahydro - 5H - Cyclohepta [B]Pyridin-9 -Yl- 4 - (2 - Oxo-2, 3 - Dihydro - 1H- Imidazo [4, 5 -B]Pyridin - 1 - Yl) Piperidine - 1 - Carboxylate, Hemisulfate Salt
Feb, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11083724 BIOHAVEN IRELAND Rimegepant for CGRP related disorders Mar, 2039

(16 years from now)

Drugs and Companies using RIMEGEPANT SULFATE ingredient

Treatment: Acute treatment of migraine with or without aura in adults; preventive treatment of episodic migraine in adults

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE TABLET, ORALLY DISINTEGRATING;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.